These CSCs showed high sensitivity to OXPHOS inhibitors (preferentially to oligomycin) that, when combined with targeted therapy for the KRAS pathway, could eliminate the tumour and prevent recurrence (Viale et al., 2014). Here, KRAS is linked to neoplasm.